Clinical Trial Update: Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lenvatinib plus PD-1 antibody versus TACE for intermediate-stage hepatocellular carcinoma beyond Up-to-seven criteria; study withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 antibody (PD-1 inhibitor)
• TACE

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: WITHDRAWN